Tazobactam is a beta lactamase inhibitor administered with antibiotics such as piperacillin and ceftolozane to prevent their degradation, resulting in increased efficacy. Tazobactam is an antibiotic of the beta-lactamase inhibitor class that prevents the breakdown of other antibiotics by beta-lactamase enzyme producing organisms.
- Mechanism
- Curator reviewed · 6 references
Tazobactam broadens the spectrum of piperacillin and ceftolozane by making them effective against organisms that express beta-lactamase and would normally degrade them. This occurs through the irreversible inhibition of beta-lactamase enzymes. In addition, tazobactam may bind covalently to plasmid-mediated and chromosome-mediated beta-lactamase enzymes. Tazobactam is predominantly effective against the OHIO-1, SHV-1, and TEM groups of beta-lactamases, but may also inhibit other beta-lactamases.
Tazobactam shows little antibacterial activity by itself, and for this reason, is generally not administered alone.
- Primary indication
- Tazobactam is used in combination with piperacillin or ceftolozane to broaden the spectrum of piperacillin antibacterial action, treating susceptible infections.Curator reviewed · 5 structured indications
- Formula / weight
- C10H12N4O5S · 300.291 g/mol (avg)
- First approval
- Canada, 2008 · United States, 1993 · European Union, 2020
- Code names
- CL-298741 · YTR-830H
- Brand names
Resolves to
LPQZKKCYTLCDGQ-WEDXCCLWSA-NSMILES[H][C@@]12CC(=O)N1[C@@H](C(O)=O)[C@](C)(CN1C=CN=N1)S2(=O)=OWhat you can answer from here — as of September 23, 2026
Which drugs share a target with Tazobactam, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account